t 11

c9,t11,c15-CLNA is an isomer of conjugated linolenic acid (CLNA) produced by Lactobacillus plantarum ZS2058. This compound demonstrates significant anti-colorectal cancer cell proliferation activity (IC50: 18.26 μM). It induces pyroptosis by activating the caspase-1-mediated classical pyroptosis pathway. c9,t11,c15-CLNA can be utilized in colorectal cancer research.

t9,t11,c15-CLNA is an isomer of conjugated linolenic acid (CLNA) produced by Lactobacillus plantarum ZS2058. It exhibits key activities including anti-inflammatory and antioxidant effects, as well as enhancement of intestinal barrier function. The regulatory mechanisms of t9,t11,c15-CLNA involve the upregulation of tight junction proteins, the inhibition of pro-inflammatory cytokines (such as TNF-α, IL-6), and the activation of antioxidant enzymes (such as SOD, CAT). t9,t11,c15-CLNA can be utilized in research on inflammatory bowel disease (like colitis).

c9,t11-CLA is an active isomer of conjugated linoleic acid (CLA) known for its various physiological activities, including anti-cancer, anti-atherosclerosis, anti-obesity, anti-diabetic, and anti-hypertensive effects. Its primary regulatory mechanisms involve modulating cell signaling pathways and metabolic processes. c9,t11-CLA can be utilized in the development of functional foods, pharmaceuticals, and health-related research.

11-Maleimidoundecane-1-carbonyl-1-(t-butyl)carbazate is a reagent used in biochemical reactions.

Azido-PEG11-t-butyl ester is a PROTAC linker within the PEG category, utilized in the synthesis of PROTAC molecules. As a click chemistry reagent, it features an Azide group that can engage in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAC) with alkyne-containing molecules. Additionally, it participates in strain-promoted azide-alkyne cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

t-Boc-Aminooxy-PEG11-amine is a PROTAC linker from the PEG class, suitable for synthesizing PROTAC molecules.

Bis-PEG11-t-butyl ester is a homofunctional, disubstituted PEG derivative employed in drug delivery.

t-Boc-N-Amido-PEG11-Tos is a PEG linker featuring a tosyl group and a Boc-protected amine. The hydrophilic PEG spacer enhances the compound's solubility in aqueous environments. The tosyl group serves as an excellent leaving group in nucleophilic substitution reactions. Under mild acidic conditions, the Boc group can be deprotected to yield a free amine.

Tos-PEG11-t-butyl ester is a PEG linker that incorporates a t-butyl ester and a tosyl group. The hydrophilic PEG spacer enhances its solubility in aqueous media. The t-butyl-protected carboxyl group can be deprotected under acidic conditions. The tosyl group serves as an excellent leaving group in nucleophilic substitution reactions.

Anticancer agent 110 is an anticancer compound with cytotoxic, antitumor, and antileukemic activity that triggers DNA damage and apoptosis and is used in the study of chronic granulocytic leukemia.

TLR7/8 agonist 11 (compound 30) serves as a powerful agonist for hTLR7 and hTLR8, exhibiting EC50 values of 31.1 nM and 13.1 nM, respectively. This compound is crucial in the functioning of both adaptive and innate immune responses.

Antifungal agent 114 (Compound 19g) serves as an inhibitor of Cytochrome P450 (Cytochrome P450), effectively suppressing CYP2C9, CYP2C19, CYP2D6, and CYP3A4 at 10 μM. It exhibits antifungal activity against Cryptococcus neoformans, Candida, and Aspergillus, with an MIC of less than 0.0625 μg/mL. Additionally, Antifungal agent 114 demonstrates favorable metabolic stability in human liver microsomes with a half-life of 107 minutes.

Antifungalagent 117 is a bipyrrole carboxamide derivative with antifungal activity, exhibiting an EC50 value of 11.58 mg/L against Sclerotinia sclerotiorum. This compound induces cell death by increasing cell membrane permeability, causing an imbalance in osmotic pressure between the interior and exterior of the cell. It also promotes oxidative damage to the cell membrane by inducing the accumulation of reactive oxygen species (ROS), leading to the leakage of cellular contents. RNA sequencing analysis has demonstrated that Antifungalagent 117 disrupts cell membrane structure by downregulating catalase genes and upregulating neutral ceramidase genes, accelerating ceramide metabolism and hastening cell death. The compound holds significant potential for application in plant protection and the control of fungal infections.

Antifungalagent 110 exhibits antifungal activity against Botrytis cinerea and Rhizoctonia solani. It demonstrates significant effectiveness in inhibiting R. solani, with an EC50 value of 0.27 mg/L. Antifungalagent 110 shows promise for use in plant disease research.

Antifungalagent 116 (compound 1a) exhibits broad-spectrum antifungal (fungal) activity.

Antifungalagent 115 (compound 8n) is a non-competitive inhibitor of chitin synthase (CHS), displaying an IC50 of 93 µM. It exhibits both broad-spectrum antifungal activity and significant efficacy against resistant fungi. Antifungalagent 115 is useful for studies on fungal infections.

FXR agonist11 (Compound 14) is an FXR activator with an EC50 of 1.2 μM and a maximal effect of 73.7%. It significantly increases GSH levels in the liver and is used to study drug-induced liver injury.

Antibacterialagent 119 (Compound 21 g) is a potential antibacterial agent effective against methicillin-resistant Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of less than 1 μg/mL against tested strains. It induces reactive oxygen species (ROS) generation and disrupts bacterial cell membranes, causing their rupture. Antibacterialagent 119 exhibits strong antimicrobial activity, low cytotoxicity, rapid bactericidal action, and favorable in vivo antibacterial efficacy.

AR antagonist 11 (Compound c2) is a selective androgen receptor antagonist with an IC50 of 0.019 μM. It is also effective against the ARF877L/T878A mutant (IC50: 1.03 μM). Additionally, AR antagonist 11 inhibits LNCaP cell proliferation and decreases PSA protein expression (IC50: 0.54 μM). This compound is applicable in prostate cancer (PCa) research.

TRPV1 antagonist 11 (compound 2ac) is a highly potent TRPV1 antagonist with an IC50 of 29.3 nM. It also acts as a μ-opioid receptor (MOR) agonist with a Ki of 60.3 nM. This pyrimidinylpiperazine compound provides analgesic effects by antagonizing TRPV1 and activating MOR. In mouse models of formalin-induced pain, TRPV1 antagonist 11 demonstrates effective dose-dependent antinociceptive properties.

Anti-MRSA agent 11 demonstrates strong activity against both fluoroquinolone-sensitive strain USA500 and resistant MRSA strain Mu50, with a MIC value of 0.39 μg/mL. It also possesses a favorable in vivo half-life and safety profile.

Neuroprotective agent 11 (Compound 1a) is an orally active polyphenolic compound that offers significant protection against cerebral ischemia. Its primary activities include inhibiting neuronal inflammation and apoptosis, reducing cerebral infarct size, and improving behavioral symptoms in mice with cerebral ischemia. The mechanism involves downregulating inflammatory factors (iNOS, COX-2) and apoptotic proteins (cleaved-Caspase3, p53). Neuroprotective agent 11 is applicable for research in ischemia-related brain diseases, such as ischemic stroke.

Dinoprost 11,15-dipivalte is a biochemical.

Antibacterial Agent 117, a triazole derivative, exhibits activity against R. prowazekii MetAP1 (RpMetAP1) with an IC 50 value of 15 μM, indicating its potency as an antibacterial agent. It effectively inhibits rickettsial growth, making it valuable for infection research [1].